Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm Corporate Presentation June 2019 (ASX:NOX)

SYDNEY, June 6, 2019: Noxopharm Ltd (ASX: NOX) (Noxopharm or ‘Company’) is pleased to provide the market with its updated corporate presentation for June 2019. For further inf...read more

Noxopharm’s DARRT-1 Study Fully Enrolled (ASX:NOX)

Final patient enrolled into study Topline data to be announced in Q4 2019 SYDNEY, 30 May 2019: Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to...read more

Promising Data Leads to Expansion of Noxopharm’s LuPIN Trial (ASX:NOX)

LuPIN trial to recruit additional 24 patients Additional patients to be treated with Veyonda? 1200 mg The objective is to see whether the dose-response effect seen to date will lead...read more

Noxopharm’s LuPIN Trial Demonstrates High Rates of Response (ASX:NOX)

Data published today describes positive interim results from the LuPIN trial Veyonda? (NOX66) dose-finding study 69% combined PSA response rate is higher than that observed in studies of ...read more

Noxopharm Announces DARRT Six Month Interim Data Shows Lasting Disease Control (ASX:NOX)

Long-lasting responses with Veyonda + low-dose radiotherapy in late-stage prostate cancer High proportion of disease control following a single, short course of treatment Complete resolution ...read more

Novatti Group, Appendix 4C (ASX:NOV)

Quarterly report for entities subject to Listing Rule 4.7B To view Report please download PDF attached:

Novatti Group Announces March 2019 Quarterly Update (ASX:NOV)

Highlights Inaugural $2m revenue in a quarter Payment processing revenue of $1.03m for the quarter with growth of 108% to the corresponding quarter last year Application for restricted Aut...read more

Noxopharm, Appendix 4C- March 2019 Quarter (ASX:NOX)

Veyonda clinical program continuing on plan CEP and DARRT programs to be expanded and expedited on basis of positive clinical data Pending release of DARRT-1 and LuPIN-1 interim clinical data...read more

Noxopharm Limited Changes to Board Structure (ASX:NOX)

Change in Noxopharm Limited Board Structure Dr Graham Kelly appointed Executive Chairman Mr Peter Marks appointed Non-Executive Deputy Chairman Dr Beata Niechoda appointed Specia...read more

Novatti Announces "Buy Now Pay Later" SAAS Agreement (ASX:NOV)

Highlights Sale of Buy Now Pay Later solution to power new UK entrant $300k revenue in FY19 15% investment in the client Novatti Group Limited (ASX:NOV, “Novatti”) is please...read more

Noxopharm Announces Idronoxil Confirmed as a New Immuno-Oncology Drug (ASX:NOX)

New class of immuno-oncology drug identified Activator of NK cells and CD4+ immune cells Potential to boost function of current immuno-oncology drugs. SYDNEY, April 16, 2019: Noxopharm (AS...read more

Noxopharm Announces Veyonda Chemotherapy Enhancement Program to be Expanded (ASX:NOX)

Expansion based on Final Report for Phase 1b CEP-1 study confirming positive efficacy signals in late-stage cancers U.S. study to investigate Veyonda + doxorubicin in sarcomas CEP-2 target st...read more

Novatti Announces Expansion of China Payments Partnerships & Processing (ASX:NOV)

Highlights OpenDNA partners with Novatti for Alipay and Wechat Pay processing New channel for retail, education and tourism payments for Chinese consumers B2B partnerships continue to grow...read more

Novatti Group announces IBM World Wire network foundation member (ASX:NOV)

Highlights Novatti joins IBM World Wire network as a foundation member IBM World Wire network built on blockchain technology for faster, cheaper and real time global payments. IB...read more

Novatti Group announces $2 million Capital Raising (ASX:NOV)

Novatti Group Limited (ASX:NOV) (Novatti or Company) is pleased to announced it has received commitments via a placement to professional and sophisticated investors to raise approximately $2 million (...read more

Viewing: 1 - 15 of 200 Previous | Next